Abstract
* Fingolimod (Gilenya) has been approved for the prevention and mitigation of relapses in relapsing multiple sclerosis.
* It's the first oral drug approved for these purposes.
* Fingolimod carries risks of several serious adverse effects, including bradyarrhythmias, infection, macular edema, respiratory complications, and increases in liver enzyme levels